Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Recruiting Phase 2 Interventional

Psilocybin for Opioid Use Disorder (OUD)

NCT06796062
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Albuquerque, New Mexico • Brooklyn, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

NCT02139046
View directory record Official record
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

NCT00889486
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 31, 2026, 1:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Effects of CBD Products on Anxiety Among U.S. Women

NCT05108220
View directory record Official record
Conditions
Anxiety, Generalized Anxiety Disorder
Interventions
Cannabidiol (CBD)- containing consumer products
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
24 Years to 44 Years · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 1:36 PM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 1:36 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-dose Study of LY3031207 in Healthy Participants

NCT01632566
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, LY3031207, Celecoxib, Simvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

NCT04232683
View directory record Official record
Conditions
Urinary Retention
Interventions
Tamsulosin 0.4Mg Capsule, Placebo oral tablet
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 1:36 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Nutraceutical Efficacy for rUTI

NCT03395288
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
D-Mannose
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

NVA237 BID Versus Placebo Twelve-week Efficacy Study

NCT01715298
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
59
States / cities
*See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 31, 2026, 1:36 PM EDT
Terminated Phase 1Phase 2 Interventional

MitoQ for Fatigue in Multiple Sclerosis

NCT03166800
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
Mitoquinone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

NCT07132801
View directory record Official record
Conditions
NAD, NAD+ Levels in the Blood
Interventions
Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, Placebo
Dietary Supplement
Lead sponsor
Qualia Life Sciences
Industry
Eligibility
35 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

NCT01688934
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 31, 2026, 1:36 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RESTOR: PK/PD mTORi Inhibition in Older Adults

NCT06658093
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Everolimus, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotic and Gastrointestinal Symptoms Due to Menstruation in Healthy Women

NCT04457401
View directory record Official record
Conditions
Menstrual Discomfort
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Results available

Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)

NCT01517711
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Tramadol, Placebo
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

NCT01001767
View directory record Official record
Conditions
HIV Infections, Heart Disease
Interventions
Lovaza, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

NCT05503511
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 31, 2026, 1:36 PM EDT
Withdrawn Phase 2 Interventional

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

NCT01142700
View directory record Official record
Conditions
Chronic Hepatitis C Virus Genotype 1
Interventions
BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Oct 31, 2026, 1:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

NCT02967692
View directory record Official record
Conditions
Melanoma
Interventions
Spartalizumab, Placebo, Dabrafenib, Trametinib
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
12
States / cities
Encinitas, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 31, 2026, 1:36 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

NCT04880109
View directory record Official record
Conditions
COVID-19
Interventions
APX-115, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 1 Interventional Results available

SXC-2023 Cocaine Interaction Study

NCT06343532
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
SXC-2023, SXC-2023 Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02240030
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301 Low Dose, CVT-301 High Dose, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 31, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

NCT04313634
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Quercetin, Fisetin
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
60 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 31, 2026, 1:36 PM EDT